APA

Mavoko H. M., Nabasumba C., da Luz R. I., Tinto H., D'Alessandro U., Kambugu A., Baraka V., Rosanas-Urgell A., Lutumba P. & Van Geertruyden J. (20180205). Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. : The Lancet. Global health.

Chicago

Mavoko Hypolite Muhindo, Nabasumba Carolyn, da Luz Raquel Inocêncio, Tinto Halidou, D'Alessandro Umberto, Kambugu Andrew, Baraka Vito, Rosanas-Urgell Anna, Lutumba Pascal and Van Geertruyden Jean-Pierre. 20180205. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. : The Lancet. Global health.

Harvard

Mavoko H. M., Nabasumba C., da Luz R. I., Tinto H., D'Alessandro U., Kambugu A., Baraka V., Rosanas-Urgell A., Lutumba P. and Van Geertruyden J. (20180205). Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. : The Lancet. Global health.

MLA

Mavoko Hypolite Muhindo, Nabasumba Carolyn, da Luz Raquel Inocêncio, Tinto Halidou, D'Alessandro Umberto, Kambugu Andrew, Baraka Vito, Rosanas-Urgell Anna, Lutumba Pascal and Van Geertruyden Jean-Pierre. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. : The Lancet. Global health. 20180205.